# About This Review > About Private Label Peptide — A Metabolic & Weight Research Peptides Review — What this Metabolic & Weight research peptides review covers, how each entry is built from signed compound literature, why the domain name is not a description of the site, and where the reporting deliberately stops. **METABOLIC & WEIGHT RESEARCH / COLOPHON** What it covers, how an entry is assembled, what the domain name does and does not mean, and the questions it refuses on principle. ## What this review covers Private Label Peptide is an independent literature review of four compounds studied in metabolic and weight research: tirzepatide, semaglutide, tesamorelin and MOTS-c. It reads all four through a single question — what happened to body composition, meaning the split between fat mass and lean tissue, rather than what happened on a scale. That framing is narrower than a general peptide guide, and deliberately so. Weight loss is well covered elsewhere. The partition of that weight into fat and muscle is covered badly, mostly because the trials that generate the headline figures were not designed to report it, and because the gap between what was measured and what is claimed is where most of the misleading writing in this category lives. The four compounds are not a coherent regulatory class. Two are approved prescription medicines with several indications between them. One is approved for a single narrow indication and is off-label everywhere else. One is not approved for human use anywhere and is supplied only for laboratory research. Any page here that flattens that difference would be doing the reader a disservice, so each compound entry states its own regulatory position explicitly. ## How an entry is built Each compound entry is assembled from a signed, citation-audited body of literature for that compound, and the citations are numbered once and used consistently across the whole site. A figure appearing on a compound page carries the same reference number on the comparison page and in the FAQ, and every number resolves to an entry on the [references page](/references). Three editorial rules govern what appears. First, quantitative claims are attached to the source that produced them. Where a figure in wide circulation comes from a publication that is not in this site's reference list, that is stated in the text rather than papered over — the two body-composition percentages discussed on the [tirzepatide page](/tirzepatide) are the working example. Second, community-reported experience is rendered only where the compound record carries a verified block of it, is labelled as anecdotal and not clinical evidence, and never carries a quantity or a schedule. Two of the four compounds here have no such block, so their pages have no anecdotal section, and none has been invented to balance the layout. Third, an absence is reported as an absence. Where a trial did not measure something, the entry says the trial did not measure it, rather than substituting a plausible number from elsewhere or leaving a silence a reader might mistake for a result. ## About the name, and what this site is not The domain name borrows a phrase from contract manufacturing. It describes nothing about this site's activity. There is no laboratory, no compounding, no inventory and no supply chain behind it. Stated concretely: this review names no vendor, quotes no price, compares no source, links to no shop and offers no sourcing guidance. It publishes no protocol, no schedule and no quantity for any person to follow. Where a dose appears on these pages it is a factual description of what a cited study administered under clinical supervision — a property of the study, not a recommendation to anyone. It is also not a clinic. It carries no clinician, gives no medical advice, cannot assess an individual case and has no view on whether any compound is appropriate for any reader. Those judgements require a diagnosis, a history and a prescriber, and none of the three can be supplied by a research summary. ## Where the reporting stops Three lines are held on every page. No human dosing. The evidence base contains study protocols, not instructions, and the difference is the entire distinction between describing research and practising medicine at a distance. No generalisation past the population studied. A result obtained in adults with HIV-associated lipodystrophy is reported as a result obtained in adults with HIV-associated lipodystrophy [12]. A result obtained in mice is reported as a result obtained in mice [20]. Mechanistic plausibility is not treated as evidence, however tidy the story it would make. No conclusion the instruments can support less than fully. A scale reading is not a fat measurement. An impedance estimate is not densitometry. A biomarker association is not a treatment effect [18]. Where the available instrument cannot decide a question, this review says so and leaves it undecided, which is less satisfying than a verdict and considerably more useful. --- Private Label Peptide is a review of published metabolic-peptide research that keeps the instrument in view — what each study weighed, scanned or only estimated, and in which population — and it prescribes nothing, dispenses nothing and supplies nothing.